Piramal Stays The M&A Course; Snaps Up Niche Mallinckrodt Assets
Executive Summary
India’s Piramal group continues its buying spree, snapping up Mallinckrodt’s intrathecal therapy business, as it seeks limited competition niches to plough deeper into the $20bn-plus global generic injectable hospital drugs market.